loading
Precedente Chiudi:
$22.93
Aprire:
$22.09
Volume 24 ore:
348.89K
Relative Volume:
0.10
Capitalizzazione di mercato:
$16.14B
Reddito:
$220.00K
Utile/perdita netta:
$-746.08M
Rapporto P/E:
-21.55
EPS:
-1.0074
Flusso di cassa netto:
$-211.81M
1 W Prestazione:
-2.38%
1M Prestazione:
+14.89%
6M Prestazione:
-16.72%
1 anno Prestazione:
+7.46%
Intervallo 1D:
Value
$21.20
$22.20
Intervallo di 1 settimana:
Value
$21.14
$25.49
Portata 52W:
Value
$15.55
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Nome
Summit Therapeutics Inc
Name
Telefono
305-203-2034
Name
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Name
Dipendente
159
Name
Cinguettio
@summitplc
Name
Prossima data di guadagno
2025-08-08
Name
Ultimi documenti SEC
Name
SMMT's Discussions on Twitter

Confronta SMMT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SMMT
Summit Therapeutics Inc
21.73 15.86B 220.00K -746.08M -211.81M -1.0074
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
409.57 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.83 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.78 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.22 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
317.60 35.16B 4.56B -176.77M 225.30M -1.7177

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-17 Iniziato Barclays Underweight
2025-09-04 Iniziato Guggenheim Buy
2025-08-19 Iniziato Piper Sandler Neutral
2025-07-01 Iniziato UBS Buy
2025-06-11 Iniziato Leerink Partners Underperform
2025-03-26 Aggiornamento Citigroup Neutral → Buy
2025-03-21 Iniziato Cantor Fitzgerald Overweight
2025-03-12 Iniziato Evercore ISI Outperform
2025-02-28 Iniziato Goldman Buy
2025-01-08 Iniziato Truist Buy
2024-12-11 Iniziato Wells Fargo Overweight
2024-12-06 Iniziato Jefferies Buy
2024-11-04 Iniziato JMP Securities Mkt Outperform
2024-09-27 Downgrade Citigroup Buy → Neutral
2024-08-12 Iniziato H.C. Wainwright Buy
2024-05-07 Iniziato Citigroup Buy
2024-03-26 Iniziato Stifel Buy
2018-06-28 Downgrade Janney Buy → Neutral
2018-05-02 Iniziato Janney Buy
2018-04-12 Reiterato Needham Buy
2018-02-13 Iniziato BTIG Research Buy
2018-01-04 Iniziato SunTrust Buy
2017-12-01 Ripresa H.C. Wainwright Buy
2016-11-16 Reiterato RBC Capital Mkts Outperform
2016-10-05 Reiterato Needham Buy
2016-09-16 Iniziato H.C. Wainwright Buy
2015-03-30 Iniziato Needham Buy
2015-03-30 Iniziato Oppenheimer Outperform
Mostra tutto

Summit Therapeutics Inc Borsa (SMMT) Ultime notizie

pulisher
Oct 13, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire

Oct 13, 2025
pulisher
Oct 13, 2025

Will Summit Therapeutics Inc. stock continue dividend increasesQuarterly Risk Review & Real-Time Buy Zone Alerts - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Summit Therapeutics Inc. stock momentum explainedJuly 2025 Review & High Conviction Investment Ideas - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Can Summit Therapeutics Inc. hit a new high this monthBuy Signal & Accurate Entry/Exit Alerts - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Statistical indicators supporting Summit Therapeutics Inc.’s strengthBear Alert & Growth Focused Investment Plans - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Will Summit Therapeutics Inc. stock gain from lower inflationJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

What drives Summit Therapeutics Inc stock priceSector Performance Drivers & Rapid Capital Portfolio - earlytimes.in

Oct 12, 2025
pulisher
Oct 12, 2025

APEIRON CAPITAL Ltd Takes $25.56 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Automated trading signals detected on Summit Therapeutics Inc.IPO Watch & Stepwise Entry and Exit Trade Signals - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

Summit Therapeutics stock reaffirmed Buy at UBS ahead of ESMO data - Investing.com

Oct 10, 2025
pulisher
Oct 10, 2025

Has Summit Therapeutics Inc. formed a bullish divergenceWeekly Investment Recap & Consistent Return Investment Signals - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Positive Outlook for Summit Therapeutics Driven by Anticipated HARMONi-6 Trial Success - TipRanks

Oct 10, 2025
pulisher
Oct 09, 2025

Is Summit Therapeutics Inc. stock supported by strong cash flowsGold Moves & Low Drawdown Momentum Trade Ideas - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Summit Therapeutics' (SMMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 08, 2025

Where is Summit Therapeutics (SMMT) Headed According to Analysts? - Yahoo Finance

Oct 08, 2025
pulisher
Oct 06, 2025

Public Employees Retirement System of Ohio Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Summit Therapeutics Inc. (SMMT) Stock Analysis: Unveiling a 51.75% Potential Upside in the Biotech Arena - DirectorsTalk Interviews

Oct 06, 2025
pulisher
Oct 06, 2025

How to use Fibonacci retracement on Summit Therapeutics Inc.Gap Up & Community Verified Trade Signals - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

1 Monster Stock in the Making to Buy and Hold - Yahoo Finance

Oct 05, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 07:31:28 - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

How to monitor Summit Therapeutics Inc. with trend dashboards2025 Market Sentiment & Community Driven Trade Alerts - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance

Oct 02, 2025
pulisher
Oct 02, 2025

H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN

Oct 02, 2025
pulisher
Oct 01, 2025

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga

Oct 01, 2025
pulisher
Oct 01, 2025

Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo

Oct 01, 2025
pulisher
Oct 01, 2025

Summit Therapeutics (NASDAQ:SMMT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat

Oct 01, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 03:00:28 - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Summit Therapeutics Shares Tumble As Lung Cancer Drug Disappoints Abroad - Finimize

Sep 30, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 00:09:58 - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN

Sep 29, 2025
pulisher
Sep 29, 2025

What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in

Sep 29, 2025

Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Summit Therapeutics Inc Azioni (SMMT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Zanganeh Mahkam
Co-Chief Executive Officer
Sep 11 '25
Buy
18.07
5,000
90,350
556,093,090
DUGGAN ROBERT W
Co-Chief Executive Officer
Sep 10 '25
Buy
17.68
333,394
5,894,406
556,088,090
DUGGAN ROBERT W
Co-Chief Executive Officer
Sep 11 '25
Buy
18.07
5,000
90,350
556,093,090
Zanganeh Mahkam
Co-Chief Executive Officer
May 30 '25
Option Exercise
2.64
74,545
196,799
555,754,696
DUGGAN ROBERT W
Co-Chief Executive Officer
May 30 '25
Option Exercise
2.64
74,545
196,799
555,754,696
$83.65
price down icon 1.13%
$32.23
price down icon 1.36%
$101.80
price down icon 0.53%
$162.72
price down icon 0.58%
biotechnology ONC
$317.44
price down icon 3.05%
Capitalizzazione:     |  Volume (24 ore):